Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

271.46 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 302
Open 271.46
Bid (Size) 270.19 (3)
Ask (Size) 271.33 (1)
Prev. Close 271.46
Today's Range 271.46 - 271.46
52wk Range 211.71 - 296.67
Shares Outstanding N/A
Dividend Yield 2.59%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Check Out What Whales Are Doing With AMGN
Via Benzinga
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates

Performance

YTD
+3.75%
+3.75%
1 Month
+4.13%
+4.13%
3 Month
+19.56%
+19.56%
6 Month
+18.11%
+18.11%
1 Year
+19.21%
+19.21%

More News

Read More
Amgen Unusual Options Activity
Via Benzinga
3 Quality Dividend Stocks For A Bear Market
Via Talk Markets
Topics Economy
Exposures Economy
$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today
Via Benzinga
2 Top Dividend Stocks to Buy in September
Via The Motley Fool
How Is The Market Feeling About Amgen?
Via Benzinga
8 Analysts Have This to Say About Amgen
Via Benzinga
$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,200 Today
Via Benzinga
These 3 Health Care Stocks With Over 3% Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
Via Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
Via InvestorPlace
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
Via Benzinga
Longeveron (NASDAQ: LGVN) Reports 100% 5-Year Survival In Trial For Rare Pediatric Disease HLHS (Compared To 80% Survival In Historical Trials) To Market
Via Benzinga
3 Growth Stocks to Buy in September
Via MarketBeat
Topics Economy
Exposures Economy
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks, Shield From Drug Pricing Negotiations
Via Benzinga
Should You Still Buy the Dow Jones' Best-Performing August Stocks?
Via The Motley Fool
Topics Stocks
Exposures US Equities
The 3 Most Promising Dow Stocks to Own Now
Via InvestorPlace
Topics Stocks
Exposures US Equities
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Via The Motley Fool
Stock Market Rally Gains Momentum As Treasury Yields Slide; Tesla Unveils Model 3 Upgrade: Weekly Review
Via Investor's Business Daily
Amgen-Horizon Therapeutics $28B Acquisition: Federal Trade Commission Gives Green Signal
Via Benzinga
Amgen, Horizon Therapeutics Stocks Jump After FTC Clears Their $28 Billion Marriage
Via Investor's Business Daily
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
From Horizon Therapeutics plc and Amgen
Via Business Wire
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Via MarketBeat
Topics Economy
Exposures Interest Rates
Is This the Green Light Biotech Stocks Have Been Waiting For?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.